Please sign in to follow a disease.
Epstein-Barr virus infection
MONDO:0005111An infection that is caused by Epstein-Barr virus.
Also known as: EBV infection, Epstein-Barr Virus infection, Human gammaherpesvirus 4 caused disease or disorder, Human gammaherpesvirus 4 disease or disorder, Human gammaherpesvirus 4 infectious disease, EBV infections, Epstein Barr Virus infections, Herpesvirus 4 infections, Human
77 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Could this mRNA vaccine stop the virus behind mono and certain cancers?
⭐️ VACCINE ⭐️ OngoingThis study is testing an experimental mRNA vaccine called mRNA-1189 to see if it can safely prevent Epstein-Barr virus (EBV) infection in healthy people aged 10 to 30. EBV is a common virus that can cause mononucleosis and has been linked to some cancers. The vaccine is given as …
Phase: PHASE1, PHASE2 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:29 UTC
-
Moderna launches first human test of mRNA vaccine against Epstein-Barr virus
⭐️ VACCINE ⭐️ OngoingThis early-stage trial is testing an experimental mRNA vaccine called mRNA-1195 to see if it is safe and triggers an immune response against Epstein-Barr virus (EBV). The study involves 482 healthy adults aged 18 to 55, some of whom have had EBV before and some who have not. Part…
Phase: PHASE1 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 07:52 UTC
-
Suicide Gene-Equipped t cells aim to make stem cell transplants safer
Disease control OngoingThis trial tests whether specially modified T cells from a partially matched donor can help patients recover their immune system faster after a stem cell transplant. The T cells are engineered with a 'suicide gene' that allows doctors to destroy them if they cause graft-versus-ho…
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Lab-Grown immune cells take aim at Life-Threatening viruses in vulnerable patients
Disease control ENROLLING_BY_INVITATIONThis study tests whether specially grown immune cells can fight three common viruses—adenovirus, CMV, and EBV—in people whose immune systems are weak due to a stem cell or organ transplant, or an inherited immune disorder. The cells are made from a donor's blood and trained to re…
Phase: PHASE1, PHASE2 • Sponsor: Paul Szabolcs • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug targets virus to fight rare cancer
Disease control OngoingThis phase 2 trial tests a drug called VK-2019 in 13 patients with Epstein-Barr virus (EBV)-positive nasopharyngeal cancer that has returned or spread and has no standard treatment. VK-2019 works by blocking a key viral protein, EBNA1, which the virus needs to survive. The main g…
Phase: PHASE2 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Blood test could guide chemo for throat cancer patients
Disease control OngoingThis study tests whether a blood test for Epstein-Barr virus (EBV) DNA can help doctors choose the best chemotherapy after standard radiation for nasopharyngeal cancer. About 685 patients will first receive standard chemoradiation. Then, based on whether EBV DNA is still detectab…
Phase: PHASE2, PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New cell therapy targets Epstein-Barr virus in immune-compromised patients
Disease control OngoingThis study tests an experimental cell therapy called tabelecleucel in 190 people with diseases caused by the Epstein-Barr virus (EBV), including certain lymphomas and post-transplant complications. The treatment uses specially prepared immune cells to fight the virus. The main go…
Phase: PHASE2 • Sponsor: Pierre Fabre Medicament • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Hospital at home: new study tests home care for infections
Disease control OngoingThis study looks at whether a special team of doctors and nurses can treat adults with suspected infections at home, instead of sending them to the hospital. About 500 people will be randomly assigned to either standard hospital care or home-based care from a mobile response team…
Phase: NA • Sponsor: Copenhagen University Hospital at Herlev • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Experimental drug brincidofovir targets Hard-to-Treat lymphomas
Disease control TerminatedThis study tests an experimental drug called brincidofovir in people with lymphoma (a type of blood cancer) that has returned or not improved after standard treatments. The trial has two parts: first, finding a safe dose in up to 18 people with various lymphomas, then testing tha…
Phase: PHASE1, PHASE2 • Sponsor: SymBio Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Immunotherapy combo shows promise for Hard-to-Treat stomach cancers
Disease control OngoingThis phase II trial is testing whether giving the immunotherapy drug pembrolizumab before standard chemotherapy and radiation can help prevent stomach cancer from coming back. It includes 40 people with operable stomach cancer that has either a specific DNA repair problem (mismat…
Phase: PHASE2 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Supercharged immune cells take on post-transplant viruses
Disease control OngoingThis study tests a new way to treat viral infections that often occur after a solid organ transplant. Researchers create special immune cells, called viral-specific T-cells, from the patient's own blood to fight the virus. The goal is to reduce the need for strong anti-viral drug…
Phase: PHASE2 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Scientists compare immune responses to viral and bacterial infections in ICU patients
Knowledge-focused OngoingThis study looks at how the immune system of patients in the intensive care unit (ICU) responds to severe infections caused by viruses or bacteria. Researchers will take extra blood samples from 38 adults to analyze immature granulocytes, a type of immune cell. The goal is to see…
Phase: NA • Sponsor: University Hospital, Limoges • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Scientists watch EBV wake up in healthy young people
Knowledge-focused OngoingThis study follows about 100 healthy adults aged 18 to 29 who have had Epstein-Barr virus (EBV) in the past. Researchers collect blood and saliva samples over 6 to 12 months to see when the virus becomes active again and how the immune system responds. No treatments or vaccines a…
Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
AI predicts hospital stays, but study never started
Knowledge-focused TerminatedThis study aimed to see if a computer could learn to predict how long a patient would stay in a home hospital program. Researchers planned to use data from past patients to train the computer. However, the study was withdrawn before any patients were enrolled, so no results are a…
Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Immune cell showdown: autoimmune vs. infection vs. healthy
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at immune cells from people with autoimmune diseases (like lupus), people with infections, and healthy volunteers. Researchers want to understand how these cells differ and what makes them attack the body in autoimmune conditions. The study involves blood and bon…
Sponsor: Emory University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC